全球神经生物标记市场规模、份额、趋势和成长分析报告（2026-2034）

预计神经生物标记市场将从 2025 年的 111.8 亿美元成长到 2034 年的 289.8 亿美元，2026 年至 2034 年的复合年增长率为 11.16%。

随着研究机构和製药公司日益重视精准医疗，神经生物标记市场正在快速发展。在阿兹海默症、帕金森氏症和多发性硬化症等复杂的神经系统疾病中，生物标记在早期诊断、药物反应监测和治疗策略制定方面发挥着越来越重要的作用。随着对临床试验和分子诊断平台投入的不断增加，以及基因组学、蛋白质组学和影像技术的融合，该领域有望进一步发展。这种发展不仅将提高诊断准确性，还将为个人化医疗铺路，从而显着改善患者的治疗效果。

数位健康工具正进一步推动对神经生物标记的需求，尤其是在人工智慧和机器学习的帮助下，能够快速检验复杂的数据集。穿戴式装置和数位诊断技术正在收集认知功能和神经生理参数的即时数据，这些数据与已验证的生物标记相结合，可实现全面的疾病监测。在药物研发过程中，生物标记正越来越多地被纳入试验通讯协定，以识别最有可能对标靶治疗反应的患者亚群，从而加快核准流程并降低药物研发的失败率。

未来几年，我们预计生技公司、诊断公司和医疗保健系统之间将进行更深入的跨学科合作，从而推动生物标记检验和商业化的扩展。随着监管机构完善其生物标记合格框架，可重复性和临床效用将变得日益重要。此外，向脑脊髓液液态生物检体和血液检测等微创检测方法的转变将提高全球神经系统生物标记检测的可及性和扩充性。这种创新与临床整合的融合正在将该市场打造为未来神经退化性疾病管理的基础。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球神经生物标记市场：依产品类型划分

• 市场分析、洞察与预测
• 蛋白质体学生物标誌物
• 基因生物标誌物
• 代谢生物标记
• 诊断影像
• 其他类型的生物标记

第五章 全球神经生物标记市场：依疾病类型划分

• 市场分析、洞察与预测
• 阿兹海默症
• 帕金森氏症
• 泛自闭症障碍
• 癫痫
• 其他疾病

第六章 全球神经生物标记市场：依最终用途划分

• 市场分析、洞察与预测
• 医院和诊所
• 研究所
• 生物製药公司
• 其他最终用户

第七章 全球神经生物标记市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Abbott Laboratories
  • ACOBIOM
  • Alseres Pharmaceuticals Inc
  • Banyan Biomarkers Inc
  • Bio-Rad Laboratories Inc
  • DiaGenic ASA
  • Johnson & Johnson
  • Merck KGaA
  • QIAGEN NV
  • Quanterix Corporation
  • Rules-Based Medicine Inc
  • Thermo Fisher Scientific Inc

The Neurological Biomarkers Market size is expected to reach USD 28.98 Billion in 2034 from USD 11.18 Billion (2025) growing at a CAGR of 11.16% during 2026-2034.

The neurological biomarkers market is advancing rapidly as research institutions and pharmaceutical developers intensify their focus on precision medicine. Biomarkers are becoming instrumental in early diagnosis, drug response monitoring, and therapeutic decision-making for complex neurological disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. With rising investments in clinical trials and molecular diagnostic platforms, the sector is set to benefit from the integration of genomics, proteomics, and imaging technologies. This evolution will not only enhance diagnostic accuracy but also open pathways for personalized interventions, significantly improving patient outcomes.

Digital health tools are further reinforcing the demand for neurological biomarkers, particularly as artificial intelligence and machine learning enable faster interpretation of complex datasets. Wearable devices and digital diagnostics are capturing real-time data on cognitive function and neurophysiological parameters, which can be linked with validated biomarkers for comprehensive disease monitoring. Pharmaceutical pipelines are increasingly embedding biomarkers into trial protocols to identify patient subgroups most likely to respond to targeted therapies, accelerating approval timelines and reducing attrition rates in drug development.

The coming years are expected to witness deeper cross-sector collaborations between biotech firms, diagnostic companies, and healthcare systems to expand biomarker validation and commercialization. As regulatory bodies refine frameworks for biomarker qualification, greater emphasis will be placed on reproducibility and clinical utility. Moreover, the shift toward minimally invasive testing methods, such as liquid biopsies using cerebrospinal fluid or blood-based assays, will drive accessibility and scalability of neurological biomarker testing worldwide. This convergence of innovation and clinical integration positions the market as a cornerstone for the future of neurodegenerative disease management.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

• Proteomic Biomarkers
• Genomic Biomarkers
• Metabolomic Biomarkers
• Imaging
• Other Biomarker Types

By Disease Type

• Alzheimer's Disease
• Parkinson's Disease
• Autism Spectrum Disorders
• Epilepsy
• Other Diseases

By End Use

• Hospitals and Clinics
• Research Laboratories
• Biopharmaceutical Companies
• Other End Users

COMPANIES PROFILED

• Abbott Laboratories, ACOBIOM, Alseres Pharmaceuticals Inc, Banyan Biomarkers Inc, BioRad Laboratories Inc, DiaGenic ASA, Johnson Johnson, Merck KGaA, QIAGEN NV, Quanterix Corporation, RulesBased Medicine Inc, Thermo Fisher Scientific Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Proteomic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Genomic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Metabolomic Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Imaging Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Biomarker Types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Type
• 5.2. Alzheimer's Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Parkinson's Disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Autism Spectrum Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Epilepsy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Hospitals and Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Research Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL NEUROLOGICAL BIOMARKERS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product Type
  • 7.2.2 By Disease Type
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product Type
  • 7.3.2 By Disease Type
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product Type
  • 7.4.2 By Disease Type
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product Type
  • 7.5.2 By Disease Type
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product Type
  • 7.6.2 By Disease Type
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL NEUROLOGICAL BIOMARKERS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Abbott Laboratories
  • 9.2.2 ACOBIOM
  • 9.2.3 Alseres Pharmaceuticals Inc
  • 9.2.4 Banyan Biomarkers Inc
  • 9.2.5 Bio-Rad Laboratories Inc
  • 9.2.6 DiaGenic ASA
  • 9.2.7 Johnson & Johnson
  • 9.2.8 Merck KGaA
  • 9.2.9 QIAGEN N.V
  • 9.2.10 Quanterix Corporation
  • 9.2.11 Rules-Based Medicine Inc
  • 9.2.12 Thermo Fisher Scientific Inc